22.60
08-十月-24 11:37:26
15 分钟延时
股票
-1.60
-6.61%
今日范围
22.48 - 26.15
ISIN
N/A
来源
NASDAQ
MBX Biosciences Presents MBX 2109 Phase 2 Avail™ Hypoparathyroidism Trial Rationale and Design at the ASBMR 2024 Annual Meeting
30 9月 2024 07:00:00 条件 Nasdaq GlobeNewswire
MBX Biosciences Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
16 9月 2024 15:05:00 条件 Nasdaq GlobeNewswire